Our Content Hub

Key Takeaways from R&D Day 2026: From the Device Renaissance to Enlightenment

Nov 19, 2026, 9:29:59 AM / by Orchestra BioMed posted in Corporate

0 Comments

Key Takeaways from R&D Day 2026: From the Device Renaissance to Enlightenment

Orchestra BioMed Investor Relations Blog | November 2026

Read More

Key Takeaways from HRX Live 2026: Medtronic, Orchestra and KOLs Discuss AVIM Therapy & Expanding the Role of Cardiac Pacing to the Treatment of Hypertensive Heart Disease

Oct 27, 2026, 11:23:21 AM / by Orchestra BioMed posted in Corporate

0 Comments

Key Takeaways from HRX Live 2026: Medtronic, Orchestra and KOLs Discuss AVIM Therapy & Expanding the Role of Cardiac Pacing to the Treatment of Hypertensive Heart Disease

Orchestra BioMed Investor Relations Blog | October 2026

Read More

AVIM Therapy and the Medtronic–Orchestra BioMed Collaboration at HRX Live 2026

Oct 9, 2026, 3:39:05 PM / by Orchestra BioMed posted in Corporate

0 Comments

AVIM Therapy and the Medtronic–Orchestra BioMed Collaboration at HRX Live 2026

Read More

LSI Alumni Innovator Spotlight: Orchestra BioMed’s David Hochman, Darren Sherman, and Bill Little

Sep 29, 2026, 9:03:53 AM / by Orchestra BioMed posted in Corporate

0 Comments

LSI Alumni Innovator Spotlight: Orchestra BioMed’s David Hochman, Darren Sherman, and Bill Little

Read More

September Highlights: A Defined Path from Enrollment to Data to Regulatory Submission, Medtronic & Orchestra at HRX, A Milestone Payment, Healthcare Investor Conferences and More

Sep 23, 2026, 12:54:55 PM / by Orchestra BioMed posted in Corporate

0 Comments

September Highlights: A Defined Path from Enrollment to Data to Regulatory Submission, Medtronic & Orchestra at HRX, A Milestone Payment, Healthcare Investor Conferences and More

Orchestra BioMed Investor Relations Blog | September 2026

Read More

David Hochman on the State of Medtech Podcast

Sep 10, 2026, 12:15:00 AM / by Orchestra BioMed posted in Corporate

0 Comments

 

Read More

Q2 2026 Progress Brings Key Pivotal Milestones Into View

Aug 18, 2026, 9:51:16 AM / by Orchestra BioMed posted in Corporate

0 Comments

Q2 2026 Progress Brings Key Pivotal Milestones Into View

Orchestra BioMed Investor Relations Blog | August 2026

Orchestra BioMed recently announced financial results for the second quarter of 2026 and provided a business update across our two pivotal-stage cardiovascular programs. The quarter delivered meaningful clarity on the timeline for primary endpoint results from the BACKBEAT global pivotal trial (“BACKBEAT Trial”) as well as planned regulatory submissions for AVIM Therapy, assuming endpoints are met. We also continued to advance the Virtue SAB in the Treatment of Coronary In-Stent Restenosis Trial (“Virtue Trial”), our investigational device exemption (IDE) randomized pivotal trial evaluating Virtue SAB for the treatment of coronary in-stent restenosis. At the same time, we strengthened our financial foundation to support both programs through their next major milestones. 

Read More

When Partnership Drives Progress: Reflections on the Vivasure Journey

Mar 2, 2026, 10:27:08 AM / by Orchestra BioMed posted in Corporate

0 Comments

When Partnership Drives Progress: Reflections on the Vivasure Journey

The recent acquisition of Vivasure Medical by Haemonetics follows over a decade of collaboration between Vivasure and Orchestra BioMed. Over that time, Orchestra worked alongside the Vivasure team through early-stage fundraising, clinical development and next-generation advancement of the PerQseal® technology, including during the formation and evolution of Vivasure’s strategic relationship with Haemonetics.

Read More

2025 Reflections from OBIO CEO

Dec 22, 2025, 10:59:59 AM / by Orchestra BioMed posted in Corporate

0 Comments

2025 Reflections from OBIO CEO

 

Dear Fellow Shareholders,

As 2025 comes to a close, I want to take the opportunity to reflect on a year of important achievements that puts Orchestra BioMed in a very strong position for the year to come. This year saw our Company make substantive clinical, strategic, and financial progress: we advanced execution of both of our pivotal trial-stage programs, we strengthened and clarified our strategic partnerships, and we secured nearly $150 million in capital and capital commitments on favorable terms. 

Read More

Shareholder Call Series: Part 3 — Key Themes from the Analyst Q&A

Dec 2, 2025, 11:00:00 AM / by Orchestra BioMed posted in Corporate

0 Comments

Shareholder Call Series: Part 3 — Key Themes from the Analyst Q&A

 

Dear Shareholders,

To complement our two-part summary of Orchestra BioMed’s recent shareholder update call, we are highlighting the Q&A session that followed the prepared remarks. Given strong shareholder interest in the types of questions asked - and the additional clarity provided by management during the discussion - we believe a concise summary of the major themes will be helpful.

Read More